Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Herceptin
(United States) [Available] ,Herzuma
(United States) [Available] ,Kanjinti
(United States) [Available] ,Ogivri
(United States) [Available] ,Ontruzant
(United States) [Available] ,Trazimera
(United States) [Available]Synonyms :
Trastuzumab
Class :
HER2 inhibitors
Brand Name :
Herceptin
(United States) [Available] ,Herzuma
(United States) [Available] ,Kanjinti
(United States) [Available] ,Ogivri
(United States) [Available] ,Ontruzant
(United States) [Available] ,Trazimera
(United States) [Available]Synonyms :
Trastuzumab
Class :
HER2 inhibitors
Dosage forms & StrengthsÂ
Powder for injectionÂ
150 mg/vialÂ
420 mg/multidose vialÂ
Advanced cancer:
:
Initial dose for cycle 1: 8 mg/kg IV over 90 mins
Maintenance dose: 6 mg/kg IV infused over 30 to 90 minutes every 3 Weeks in combination with carboplatin and paclitaxel for 6 cycles
Gastric metastatic cancer:
Initial dose for cycle 1: 8 mg/kg IV over 90 mins
Maintenance dose: 6 mg/kg IV infused over 30 to 90 minutes every 3 Weeks in combination with cisplatin and capecitabine/fluorouracil for 6 cycles
Initial dose: 4 mg/kg IV over 90 mins
Maintenance dose: 2 mg/kg IV over 30 min every 3 Weeks during the first 12 weeks of chemotherapy, 6 mg/kg IV infused over 30 to 90 minutes every 3 Weeks for 52 weeks 1 week after chemotherapy completed
Adjuvant treatment with concurrent docetaxel/carboplatin:
Initial dose: 4 mg/kg IV over 90 mins
Maintenance dose: 2 mg/kg IV over 30 min every Week during the first 18 weeks of chemotherapy, 6 mg/kg IV infused over 30 to 90 minutes q3Weeks for 52 weeks 1 week after chemotherapy completed
Adjuvant treatment with anthracycline-based chemotherapy:
Initial dose: 8 mg/kg IV over 90 mins
Maintenance dose: 6 mg/kg IV infused over 30 to 90 minutes every 3 Weeks for 52 weeks 1 week after chemotherapy completed
Not determined Â
Refer adult dosing
Risk of infection enhanced due to increased immunosuppressive effects of trastuzumab
in combination with ofatumumab, trastuzumab increases the risk of adverse events
may increase the risk or severity of adverse effects when combined
It may enhance the toxicity effects when combined with triamcinolone by immunosuppressive effects
it may enhance the adverse effects when combined with aducanumab
when trastuzumab and melphalan combine the immunosuppressive effects of both the drugs are enhanced and lead to increased risk of infection
when both the drugs combine the effect of both drugs increases by immunosuppressive effects and increase the risk of infection.
Pharmacodynamic synergism may lead to toxicity of immunosuppressant and myelosupressant effects
when both drugs are combined, there may be a decreased level of serum concentration of paclitaxel  
when thiotepa and trastuzumab combine, the immunosuppressive effects of both the drugs are enhanced and lead to an increased risk of infection     
may enhance the risk of infection due to neutropenia
either of the drugs, if taken simultaneously, increases the toxicity levels by immunosuppression.
when both drugs are combined, there may be an increased immunosuppressive effect of both drugs and a risk of infection  
increase bone marrow suppression
risk of severe infection due to immunosuppressive effects
may enhance the risk of neutropenia due to immunosuppression
when used in combination, both the drugs increase immunosuppression/risk of infection
may enhance the risk of neutropenia due to immunosuppression
trastuzumab: may enhance the risk of neutropenia due to immunosuppression
either of the drug in combination increases the effect of the other due to immunosuppression/risk of infection
may raise the risk of neutropenia and serious infection by increasing immunosuppressant
increase bone marrow suppression
may enhance the immunosuppressive effects of each other
Actions and Spectrum:Â Â
Trastuzumab is a monoclonal antibody that prevents homodimerization and signaling. It also enhances antibody-dependent cellular cytotoxicity which causes death in HER2-expressing cells. Â
Frequency definedÂ
>10%Â
RhinorrheaÂ
nasopharyngitis Â
pulmonary toxicityÂ
rhinitis Â
Cough Â
epistaxisÂ
Black Box Warning:Â Â
 None Â
Contraindication/Caution:Â Â
Contraindications Â
Cautions Â
Pregnancy Warnings:Â
Pregnancy category: N/AÂ
Lactation: Excretion of the drug into the human breast milk is unknownÂ
Pregnancy categories:Â
Pharmacology:Â Â
Trastuzumab belongs to a class of targeted cancer drugs known as monoclonal antibodies. Â
Pharmacodynamics:Â Â
Trastuzumab works by blocking signals that make cancer cells grow and by promoting the immune system to destroy these cells. Â
Pharmacokinetics:Â Â
Limited information is available on ADME. Â
Administration:Â Â
Trastuzumab is administered through an intravenous infusion.Â
Patient information leafletÂ
Generic Name:Â trastuzumabÂ
Pronunciation: tras-TOO-zoo-mab
Why do we use Trastuzumab?Â
Trastuzumab is a targeted cancer drug known as a monoclonal antibody. It is used to treat cancers that have high levels of the HER2 protein (human epidermal growth factor receptor 2). HER2 is a protein that promotes the growth and division of cells, and some cancer cells produce excessive HER2, making them grow faster.Â
Trastuzumab is used for the treatment of:Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
